StreetAlpha.app
Home › Stocks › CVRX

CVRx, Inc. (CVRX)

Healthcare
$0.50
▼ −5.99%
LAST CLOSE · NOV 20

CVRx makes Barostim, an implantable device that uses electrical pulses to treat heart failure. It last closed at $0.50 on Nov 20, down 5.99% on the day. The next earnings report for CVRX is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, CVRX reported EPS of -$0.52 on revenue of $13.8M, with revenue down 5.8% from a year ago. Over its last 8 reports the stock moved an average of 23.0% the session after earnings. Over the last 12 months CVRX insiders bought $377K of stock on the open market and sold $221K, according to SEC Form 4 filings.

AI Auto Pilots
Is CVRX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CVRX.

Key Stats

Last 12 months
Results
Revenue
$60.3M
+7.8% vs a year ago
Net income
−$53.3M
−88.3% margin
EPS (diluted)
−$2.00
Free cash flow
−$42.0M
−69.7% margin
Valuation
Market cap
$14.3M
28.5M shares
P/E
–
No P/E while losing money
Price to sales
0.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$58.7M
At Sep 30
Debt
$58.7M
At Sep 30
Shareholder equity
$13.8M
Shares outstanding
28.5M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $13.0M$13.0MFY2021FY2022: $22.5M$22.5MFY2022FY2023: $39.3M$39.3MFY2023FY2024: $51.3M$51.3MFY2024FY2025: $56.7M$56.7MFY2025

From CVRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$0.52
Quarter ended Sep 2026
Year ago EPS
-$0.49
Same quarter last year
Revenue
$13.8M
−5.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.40Dec '24Mar 2025: -$0.53Mar '25Jun 2025: -$0.57Jun '25Sep 2025: -$0.49Sep '25Dec 2025: -$0.45Dec '25Mar 2026: -$0.50Mar '26Jun 2026: -$0.53Jun '26Sep 2026: -$0.52Sep '26Latest -$0.52
Revenue by quarter
Dec 2024: $15.3MDec '24Mar 2025: $12.3MMar '25Jun 2025: $13.6MJun '25Sep 2025: $14.7MSep '25Dec 2025: $16.0MDec '25Mar 2026: $14.8MMar '26Jun 2026: $15.7MJun '26Sep 2026: $13.8MSep '26Latest $13.8M
How CVRX moved after its last 8 reports
Average move the session after a report ±23.0%
Nov 5, 2026After the close−40.9%
Aug 6, 2026After the close−59.8%
Apr 13, 2026Time not announced+9.2%
Feb 12, 2026After the close−13.0%
Jan 12, 2026Time not announced−9.9%
Nov 5, 2025After the close+2.7%
Aug 4, 2025After the close−9.9%
May 8, 2025After the close−38.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CVRXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CVRX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CVRX

Technical Analysis

CVRX · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 100% below its 20 day and 223% below its 50 day average. It is 868% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 19), oversold. The nearest support is the 52 week low at $0.50, and the nearest resistance the Pivot at $0.52.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 28.0%/day
Key levels
$10.2852 week high+1956.0%
$4.85200 day average+870.0%
$2.85100 day average+470.0%
$1.6250 day average+224.0%
$1.49Swing high (Oct 27)+198.0%
$1.0020 day average+100.0%
$0.55Pivot R1+10.0%
$0.52Pivot+4.0%
$0.5052 week low+0.0%
$0.50Last close
$0.48Pivot S1−4.0%
Indicators
RSI (14)19.01Oversold below 30Oversold
MACD-0.32Below its signal lineBearish
Stochastic1.4Near the bottom of its rangeOversold
ADX (14)52.0Strong downtrend
Williams %R-99.7Oversold below −80, overbought above −20Oversold
CCI (20)-88.3Oversold below −100, overbought above 100Neutral
Rate of change−42.3%Change over 10 sessionsBearish
ATR (14)$0.14Typical daily range, 28.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CVRX

What happened before

See how CVRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CVRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CVRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CVRXHow many large options trades hit CVRX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CVRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲47 buying vs 40 selling
  • ▲Held by funds +0.8 pts
  • ▼Funds holding -1
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8788−1.1%
In funds' top 10110.0%
Held by funds54.5%53.7%+0.8 pts
New / increased16 / 319 / 35+6.8%
Reduced / sold out23 / 1727 / 18−11.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CVRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CVRX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$377K3 buys · 2 insiders
Sold$221K8 sales · 7 insiders
59% of the selling was under pre-arranged trading plans.
2026-02 bought $300K2026-03 sold $127K2026-08 bought $76K2026-08 sold $3KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 13Brent BinkowskiCOOBuy26,223$2.91$76K
Aug 12Brent BinkowskiCOOSale plan1,309$2.55$3K
Mar 2Philip B. AdamsonChief Medical OfficerSale plan1,262$7.90$10K
Mar 2Kevin HykesPres & CEOSale plan7,763$7.90$61K
Mar 2Jared OasheimCFOSale plan1,744$7.90$14K
Mar 2Paul VerrastroChief Mktg & Strat OfficerSale plan1,284$7.90$10K
Every insider buy and sale for CVRX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CVRX insider trades →

From SEC Form 4 filings by CVRX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CVRX is in one of them and how their past CVRX trades turned out.

CVRX in the AI portfolios
Loading…

CVRX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CVRX in an article yet. Here's the latest on the wider market.

CVRX in the news

About CVRx

CVRx makes Barostim, an implantable device that delivers electrical pulses to sensors in the wall of the carotid artery to treat heart failure with reduced ejection fraction. The device is placed in a minimally invasive outpatient procedure and is designed to work alongside standard medications. Its customers include patients with this form of heart failure, the doctors who treat them, and the healthcare payers who cover the therapy. The company is based in Minneapolis, Minnesota.

Headquarters
Minneapolis, MN
Founded
2001